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Abstract  
Microarray-based comparative genomic hybridization (aCGH) is commonly used in 
diagnosing patients with intellectual disability (ID) with or without congenital malformation. 
Since aCGH interrogates the whole genome, there is a risk of being confronted with 
incidental findings (IF). In order to anticipate the ethical issues of IF with the generalization 
of new genome-wide analysis technologies, we questioned French clinicians and 
cytogeneticists about the situations they have faced regarding IF from aCGH. Sixty-five IF 
were reported. Forty corresponded to autosomal dominant diseases with incomplete 
penetrance, 7 to autosomal dominant diseases with complete penetrance, 14 to X-linked 
diseases, and 4 were heterozygotes for autosomal recessive diseases with a high 
prevalence of heterozygotes in the population. Therapeutic/preventive measures or 
genetic counselling could be argued for all cases except 4. These 4 IF were intentionally 
not returned to the patients. Clinicians reported difficulties in returning the results in 29% of 
the cases, mainly when the question of IF had not been anticipated. Indeed, at the time of 
the investigation, only 48% of the clinicians used consents mentioning the risk of IF. With 
the emergence of new technologies, there is a need to report such national experiences; 
they show the importance of pre-test information on IF.   
 
Key Word : aCGH, ethical issues, incidental findings, pre-test information 
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Introduction 
 An incidental finding (IF) is defined as a non-deliberate finding that has potential 
health or reproductive importance for the proband or his family and is not related to the 
indication of the test. IF are not uncommon in clinical practice and recommendations about 
their report have been established. It is widely accepted that an IF should be returned 
when it reveals a condition likely to be life-threatening, a condition likely to be severe that 
can be avoided or improved, or genetic information that can be used in reproductive 
decision-making1.  
 Microarray-based comparative genomic hybridization (aCGH) has become a first-
intention diagnostic tool in intellectual disability (ID)/developmental delay (DD), 
dysmorphism, multiple congenital abnormalities (MCA), associated or not with behavioural 
disorders, seizures or aberrant growth patterns, as it allows an objective interrogation of 
chromosome structure for microscopic and submicroscopic imbalances throughout the 
genome. Human genomes exhibit substantial variation; the average diploid human 
genome differs from the reference genome by ~3 million to 3.5 million single-nucleotide 
variants (SNP) and about a thousand copy-number variants (CNVs; e.g., DNA deletions 
and duplications) >500 base pairs in size2. Most CNV do not have any clinical implication 
but some are found in human diseases, or have unknown significance. In the search for a 
CNV that causes a patient’s phenotype, there is a risk of being confronted with IF since 
aCGH is a pangenomic test. When aCGH reveals a diagnosis in a patient, the IF can be 
located either outside or within the rearrangement. In other cases, an IF could be found, 
but the cause of the phenotype may remain unknown. Ethical issues of IF after the 
prescription of aCGH have been studied by some groups3,4,5,6,7 , but the experience of 
clinicians in the transmission of the results to patients and/or their families is still 
insufficient. 
 With the arrival of new technologies such as Next Generation Sequencing (NGS) for 
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diagnostic purposes, allowing whole exome or genome sequencing, the management of IF 
will become a crucial ethical issue for medical geneticists and biologists, since they are 
expected to become more frequent. The American College of Medical Genetics and 
Genomics (ACMG) recently published a policy statement, which recommended that 
laboratories performing clinical sequencing seek and report pathogenic or probably 
pathogenic mutations in a list of 56 genes of medical value for patient care5, 8. These 
recommendations have been subject to intense discussion/controversy, thus showing the 
need to accumulate experience and advice, which might vary from one country to another 
(www.acmgfoundation.org). In particular, they emphasized the importance of disclosing the 
possibility of such results in pre-test discussions with patients. 
In order to take advantage of the experience of IF found by aCGH, we analysed the 
management of IF revealed by this technique in France over a 7-year period. 
 
 
Materiel and Methods 
 The methodology was designed to question clinicians about their experience in 
returning IF during the first 7 years of their experience with aCGH. Since the design of the 
study was retrospective, various types of array were used, from BAC array to SNP array 
with a resolution of 300K. Coverage generally increased over the 7- year study period. 
Nevertheless, Agilent 180K was the most commonly used array (30% of the laboratories). 
For the purpose of the study, we used the following definition of IF: the finding of 
pathogenic or probably pathogenic alterations in genes that are not apparently relevant to 
the diagnostic indication for which the test was ordered, but that have potential health or 
reproductive importance for the proband or his family. It differed from the ACMG 
recommendations since the search was not deliberate, but incidental8. 
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 Two different questionnaires (supplemental data 1 to 4) were produced, sent out in 
January 2014, and collected at the end of March 2014. The questionnaires had been 
validated beforehand by a group of medical geneticists, cytogeneticists, molecular 
biologists and ethicists. The first questionnaire was sent to all the French clinical 
geneticists who were members of the « Association Française des Généticiens 
Cliniciens » and involved in genetic clinics and in prenatal diagnosis (PND) on a daily 
basis. Besides administrative data (sex, age, center), the first part of the questionnaire 
included general questions such as the number of aCGH prescribed each year, the 
number of IF they had been confronted with, and the mention of the risk of IF in the 
informed consent. The second part of the questionnaire included one sheet for each IF. 
Clinicians were asked to give the sex and age range of the patient concerned, the 
coordinates of the CNV, the type of CNV (deletion or duplication), and its inheritance 
(inherited, de novo or unknown). For IF that may be responsible for an autosomal 
dominant disease, they were asked to say whether the penetrance of the disease was 
complete or incomplete, and provide the category of IF (genetic predisposition to cancer, 
to neurogenetic diseases, to cardiogenetic diseases, or to other categories of disease). In 
cases of heterozygosity for an autosomal recessive disease, the clinician was asked to 
provide the information only for frequent diseases that would usually indicate carrier 
testing in the proband’s family, according to the carrier frequency in the ethnicity 
concerned (cystic fibrosis and spinal muscular atrophy in Caucasians, for example), or rare 
variants in a consanguineous family. The clinician was then asked to say whether the IF 
was returned to the patient and/or general practitioner in charge of the patient, whether 
he/she had encountered any difficulties during the interview while returning the IF, and 
whether a psychological interview was proposed to the patient/family. The answers were 
correlated with the characteristics of the disease, i.e. if it was accessible to therapeutic or 
preventive measures, genetic counseling and/or prenatal diagnosis. The clinicians were 
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finally asked whether the decision to return the CNV was discussed in a multidisciplinary 
meeting (with other clinicians and biologists within the same genetics department) or not. 
The French cytogeneticists from the national Achropuce network were also asked to fill in 
a questionnaire in order to maximize the number of reported case. They were asked to 
give, the coordinates of the CNV, the type of CNV (deletion or duplication) and its 
inheritance (inherited, de novo or unknown), and to indicate if they returned the IF to the 
clinician. If a clinician did not declare an IF to the study reported by a cytogeneticist, 
he/she was then contacted. 
The pathogenicity of each IF declared was determined using the information available from 
public databases including OMIM (http://www.omim.org/), UCSC 
(https://genome.ucsc.edu/), Decipher (https://decipher.sanger.ac.uk/), Clingen 
(http://clinicalgenome.org/), Pubmed (http://www.ncbi.nlm.nih.gov/pubmed) and Standard 
For Cytogenomic Array (ISCA) consortium (http://dbsearch.clinicalgenome.org/). We 
classified an IF as pathogenic if it had already been reported in the literature as causing 
the disease; probably pathogenic if the IF comprised a gene in which mutations are known 
to cause the disease secondary to haploinsufficiency; of unknown significance in the 
remaining cases. In this study, we did not include susceptibility factors for disease. 
 
 
 
 
 
Results 
 We collected data from all university hospitals in France and from 55% of the 
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practitioners. Sixty-five IF (table and supplemental data 5) that corresponded to our 
definition were reported by 44 clinicians. 7 IF declared were rejected because they did not 
fit our criteria, they consisted in heterozygous status for recessive autosomal disease with 
very few heterozygotes in the general population. All the aCGH were prescribed for 
developmental delay, intellectual disabilities and/or malformations. The majority of IF were 
found in children. Eight were detected in adults and one in a fetus, after termination of the 
pregnancy. Three were diagnosed antenatally (none leading to termination of the 
pregnancy). 
 Among these 65 IF, 40 corresponded to autosomal dominant (AD) disease with 
incomplete penetrance (including 19 predispositions to cancer), 7 to AD disease with 
complete penetrance, and 14 to X-linked disease (2 in male and 12 in female carriers) 
(Table 1). Three heterozygotes for prevalent autosomal recessive (AR) disease were 
reported and one heterozygote for a rare disease in a highly consanguineous family. 
Therapeutic/preventive measures (including prenatal testing) could be argued for all cases 
except 4. Among the 65 IF, 55 (85%) were returned to the patients, but only 4/65 (6%) 
were intentionally not returned (Supplemental table). Indeed, for 5 patients, the 
consultation was either planned at the time of writing, or the family did not come to their 
appointment. The 4 results that were intentionally not returned to the patient/family 
included one paternally inherited deletion of TTBK2 that could be responsible for the 
development of spinocerebellar ataxia type 11 (OMIM #604432) in a negative family 
history, one de novo SETX deletion that could be responsible for the development of 
juvenile amyotrophic lateral sclerosis type 4 (OMIM #602433), one de novo duplication of 
PARK4  that could be responsible for the development of Parkinson disease (OMIM 
#605543) and a PMP22 deletion that could be responsible for the development of 
Hereditary Neuropathy with liability to Pressure Palsies. For the 3 first cases, and after 
discussion in a multidisciplinary meeting, the results were not returned because of the 
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uncertain significance of the rearrangements, the late onset of the symptoms, and the 
absence of treatment or preventive measures. In the fourth case, the result was not 
returned because the adult patient had not been informed of the possibility of incidental 
findings before the test. Seven of the 65 IF were due to the deletion/duplication of a gene 
included within the pathogenic CNV. In one case, a PKD2 deletion responsible for 
polycystic kidney disease (OMIM #173900) was already known in the family of the patient 
but this patient had not been diagnosed, which led us to consider this result an IF.  
  When clinicians returned the results, they reported difficulties in 19 cases (29%). In 
9/65 cases (14%), the clinician said that it was difficult to give an accurate prognosis to the 
patient/family, in cases of DMD deletion (causing Duchenne Muscular Dystrophy, OMIM), 
TP53 deletion (causing Li-Fraumeni syndrome, OMIM #151623), PMP22 duplication 
(causing Charcot-Marie-Tooth syndrome 1A, OMIM #118220), in the absence of 
symptomatic family members. In 6/65 cases (9%), the family did not understand the results 
(one carrier status for Duchenne Muscular Dystrophy, one carrier status for Farber disease 
(OMIM #228000) and four cases of PMP22 deletion). In 4/65 cases (6%), the parents 
found it difficult to cope with the announcement, in the context of a genetic predisposition 
to cancer. In 3 cases, the results were unexpected and caused parental anxiety. In 1 case, 
the parents were surprised of receiving additional information 5 years after the result of the 
pathological CNV since the IF was inside the pathogenic deletion. Indeed, the clinician 
asked the laboratory for the gene content on the occasion of a follow-up visit; information 
that was not given at the time of the first results. Among the 44 clinicians who took part in 
our study, 30 (68%) thought that consent should leave the choice to the patient to know 
his/her status for an IF, and only 21 used a consent form that mentioned the risk of IF 
(48%) at the time of the analysis in a given patient. 
 
Discussion  
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 IF are not uncommon in the medical domain and general recommendations about 
their report have been proposed. IF should be reported when there is a strong net benefit 
for the patient or his/her offspring to know the information1. The report of IF in the context 
of genetic characteristics raises additional questions since the results may have no impact 
on the health or reproduction for the patient him/herself, but may be important for his/her 
family. Therefore, specific studies are needed in order to develop specific 
recommendations. Few studies about the experience of physicians in the management of 
IF following the prescription of aCGH in routine clinical practice have been published 9,10,11, 
thus justifying the present study. 
The aim of this study was to analyze 7 years of experience regarding IF after the 
prescription of aCGH in France. The methodology used did not permit us to determine a 
reliable frequency of IF arising from aCGH since it did not involve a systematic 
bioinformatics search on standardized criteria, and only relied on the physician’s report, 
which could be subject to recall bias given the time frame of the surveyed. The majority of 
results concerned AD diseases with incomplete penetrance, inherited or not from an 
asymptomatic parent. When X-linked inheritance was concerned, it was found more 
frequent in females, with no immediate consequences for the patient, but with 
consequences for reproductive issues of the patient and relatives. Similarly, we found only 
4 carrier status for a recessive disease according to our definition, which had no 
immediate consequence for the patient but was an indication for genetic counseling for the 
family and for future pregnancies. Seven of the 65 IF were included within the pathogenic 
microdeletion/duplication, and the incidental character could be regarded as debatable 
since in some cases they may be considered part of the patient’s phenotype. Only four IF 
were detected prenatally. This may be due to the use of lower resolution array by some 
laboratories in order to avoid IF, but also because the prenatal use of aCGH is quite recent 
in France and not available in all centers.  
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 In our study, geneticists did not return the results in only 4 of the 65 cases. All of the 
geneticists gave the IF result to their patients when there was strong evidence of a benefit, 
such as treatment, particular care or genetic counseling to avoid complications. The only 
incidental results that were not returned to the family were those concerning adult-onset 
diseases with no preventive care and no available therapy, but also insufficient data for 
their pathogenicity, and the decision was made after a collegial discussion. Returning an IF 
may cause difficulties for clinicians because the consequences can be uncertain. This 
point has been learned from the experience with DMD duplications/deletions12,13,14 , not all 
DMD rearrangements are pathogenic9,15,16,17,18,19, thus underlining the importance of 
familial screening. Indeed, in our study, we found 11 cases of rearrangements comprising 
DMD. In 2 cases, the familial segregation argued in favor of a polymorphism, but returning 
the result caused anxiety in the family in the absence of formal conclusions. These data 
should lead to caution in returning the results to families, and a rearrangement should be 
considered pathogenic only when it has already been reported to be related to the disease 
in previous publications or databases. In our study, only 79% of the IF could be considered 
pathogenic or probably pathogenic. The significance was unknown in 21% of IF, thus 
making it difficult for the clinician to give an accurate prognosis and for the patient to 
understand the significance and to cope with the finding.  
Some authors suggest that the majority of patients would like to know about these 
results in order to cope and to make future reproductive decisions. These findings were 
based on telephone interviews with the parents of children affected by a rare disease,21,22  
but opinions are mixed in other studies3,4. In a study conducted by Kleiderman3 concerning 
the discovery of IF in whole exome sequencing (WES) investigations, responders 
expressed an overwhelming interest in receiving the child’s sequencing results but were 
less confident that they would want to know the results if the disorder was a highly 
penetrant and fatal adult-onset illness. For the carrier status for a recessive condition, they 
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expressed the wish to be informed later, when the information became relevant for their 
child3. These results were confirmed in a study conducted by Christenhusz4, who 
emphasized the fact that parental motivations for and against the disclosure of unexpected 
results clustered around four main themes: actionability; knowledge about the future of 
their child; context (relationship with geneticist, disabled child); and characteristics of the 
result. 
 Following these studies, it appears essential to know the wishes of each 
patient/family. However, it seems that this was not anticipated in each case since only 48% 
of the centers in our study used consent form mentioning the risk of IF at the time of the 
analysis in a given patient. Most of the geneticists answered that the consent should give 
the patient the choice of whether to know the IF or not. Nevertheless, we learned from the 
literature that patients and their families admitted they could not anticipate their own 
preferences about whether or not to receive results until they were returned, given the 
variability of the potential results and their implication3.  Another ethical debate was raised 
by the ACMG, since they published recommendations in order to systematically search for 
pathogenic mutations in 56 genes implicated in cancer predisposition or in cardiovascular 
diseases7,8,21. In the case of systematic screening for a particular gene, the term IF cannot 
be used and some authors prefer the term secondary findings. The arrival of new 
technologies raises questions about current practices in presymptomatic testing. Indeed, in 
France, presymptomatic testing in children for adult-onset diseases is not allowed, and 
requires special testing conditions for adults, including a psychological interview.  
 The largest study about IF in aCGH identified IF in almost 1% of aCGH performed 
in a routine clinical population 9. However, using exon-targeted aCGH only 40% of these IF 
were found to be pathogenic or probably pathogenic. Indeed, Boone et al used custom-
designed targeting for 24,000 exons of 1,700 clinically relevant and candidate disease-
related genes in addition to usual probes of the Agilent 180k microarray in unscreened or 
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undiagnosed individuals and their parents when available that may reveal a higher 
proportion of intragenic exonic IF15. They discovered 83 IF in a cohort of 9,005 DNA 
samples. They used a different definition since they regarded as an IF only late-onset 
disorders unrelated to the current diagnosis of the patient.  
In conclusion, this study reflects the difficulties encountered by clinicians in routine 
practice and the way they have managed them. Accurate pre-test counseling seems 
essential when prescribing this kind of pangenomic test. More studies are needed to 
evaluate the preferences of patients in the management of their IF. 
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Table: Repartition of the 65 IF.  
 
AN: Antenatal 
 
 
 
 
 
 
 
 
 
 
 
  AN  <5y  5‐18y  >18y  Total 
Inheritance 
Dominant 
autosomal 
Complete 
penetrance 
0  4  3  0  7 
Incomplete 
penetrance 
2  15  19  4  40 
Recessive autosomal 
(heterozygote status) 
1  2  1  0  4 
X‐linked  Male  0  2  0  0  2 
Female   0  6 5 1 12
Disease 
Cancer predisposition  0  13  9  0  22 
Neurological disease  1  6 11 4 20
Sudden death predisposition  1  0  1  0  2 
Carrier status  1  8  6  1  16 
Other  0  2  3  0  5 
